These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20389300)

  • 1. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    Rustin GJ; Shreeves G; Nathan PD; Gaya A; Ganesan TS; Wang D; Boxall J; Poupard L; Chaplin DJ; Stratford MR; Balkissoon J; Zweifel M
    Br J Cancer; 2010 Apr; 102(9):1355-60. PubMed ID: 20389300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
    Zweifel M; Jayson GC; Reed NS; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu SP; Balkissoon J; Chaplin DJ; Rustin GJS
    Ann Oncol; 2011 Sep; 22(9):2036-2041. PubMed ID: 21273348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of combretastatin a-4 phosphate with carboplatin.
    Bilenker JH; Flaherty KT; Rosen M; Davis L; Gallagher M; Stevenson JP; Sun W; Vaughn D; Giantonio B; Zimmer R; Schnall M; O'Dwyer PJ
    Clin Cancer Res; 2005 Feb; 11(4):1527-33. PubMed ID: 15746056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
    He X; Li S; Huang H; Li Z; Chen L; Ye S; Huang J; Zhan J; Lin T
    Br J Clin Pharmacol; 2011 Jun; 71(6):860-70. PubMed ID: 21276042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
    Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Waggoner S; Greer BE; Horowitz IR; Fowler JM; McGuire WP
    J Clin Oncol; 2000 Aug; 18(16):2957-62. PubMed ID: 10944128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
    Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
    Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
    Belani CP; Aisner J; Hiponia D; Engstrom C
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.
    Ogawara M; Kawahara M; Hosoe S; Atagi S; Kawaguchi T; Okishio K; Naka N; Sunami T; Mitsuoka S; Inoue K; Haryu H; Yoneda T; Origasa H
    Jpn J Clin Oncol; 2002 Feb; 32(2):48-53. PubMed ID: 11948228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.